The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Agents

Background: Hyperkalemia is a potentially life-threatening disorder frequently occurring in hospitalized patients. The ischemic myocardium releases potassium into the extracellular space which can cause regional hyperkalemia. These changes may modify the effects of anti-arrhythmic drugs acting on th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiology 2007-01, Vol.108 (1), p.18-27
Hauptverfasser: Lin, Congrong, Ke, Xiaogang, Cvetanovic, Ivana, Ranade, Vasant, Somberg, John
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 27
container_issue 1
container_start_page 18
container_title Cardiology
container_volume 108
creator Lin, Congrong
Ke, Xiaogang
Cvetanovic, Ivana
Ranade, Vasant
Somberg, John
description Background: Hyperkalemia is a potentially life-threatening disorder frequently occurring in hospitalized patients. The ischemic myocardium releases potassium into the extracellular space which can cause regional hyperkalemia. These changes may modify the effects of anti-arrhythmic drugs acting on the rapid component of the delayed rectifier potassium current (IKr). We evaluated the influence of increased extracellular potassium concentration [K + ] e on IKr inhibition by amiodarone, azimilide, dofetilide, quinidine and sotalol. Methods and Results: Experiments were performed at room temperature. IKr current was studied by using HERG gene expressed in Xenopus oocytes as a model of cardiac IKr. Two-electrode voltage clamp technique was employed. The recording bath solutions contained either 5 or 10 mmol/l KCl. Amiodarone, azimilide, dofetilide, quinidine and sotalol all produced a dose-dependent inhibition of HERG current. At 5 mmol/l [K + ] e , the IC 50 was 37.0 ± 12.5 µM for amiodarone, 5.8 ± 0.4 µM for azimilide, 1.5 ± 0. 2 µM for dofetilide, 9.1 ± 1.5 µM for quinidine, and 5.1 ± 0.8 mM for sotalol. Raising the extracellular potassium to 10 mmol/l, HERG block by azimilide, dofetilide, quinidine and sotalol was significantly decreased, while the block by amiodarone was unchanged. The differences in the percentage current block produced by 3 µM drugs at 5 and 10 mmol/l [K + ] e were: –0.9% for amiodarone, 13.8% for quinidine, 20.5% for azimilide, and 16.2% for dofetilide. The differences in percentage block between 5 and 10 mmol/l [K + ] e by sotalol 10 and 30 mM were 7.1 and 5.6%. At 10 mmol/l [K + ] e , the IC 50 was increased for azimilide, dofetilide, quinidine and sotalol but not for amiodarone; the IC 50 was 24.7 ± 7.4 µM for amiodarone, 29.3 ± 3.9 µM for azimilide, 2.7 ± 0.2 µM for dofetilide, 27.6 ± 4.0 µM for quinidine, and 7.2 ± 1.7 mM for sotalol. Conclusion: Inhibition of IKr by azimilide, quinidine, dofetilide and sotalol was diminished by increasing [K + ] e , while the inhibition by amiodarone was unchanged at normal and high [K + ] e . The differential effects of azimilide, dofetilide, quinidine and sotalol at normal and high [K + ] e could be pro-arrhythmic by favoring re-entry arrhythmias. These results further support the unique electrophysiological effect of amiodarone.
doi_str_mv 10.1159/000095596
format Article
fullrecord <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_95596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1313138901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-4cacdff503acc692f53257594ab05a3e5a6ac2ba5fdf02468002cf5ca25a1ef23</originalsourceid><addsrcrecordid>eNpdkEtLAzEUhYMotlYXrgUJLgQXo3lPZzmUaosFXVS3QyZNOqnzqEkG7L93ypQK3s3lXL57OBwArjF6xJgnT6ibhPNEnIAhZgRHSczxKRh253EkKCYDcOH9ppMsZuQcDLBIBGKMDcHnstBwaoxWATYGzuy6gNOf4KTSZdmW0sH3JkjvbVvBpobzVwfndWFzG2wn8x1M62Cj1LliF4rKKpiudR38JTgzsvT66rBH4ON5upzMosXby3ySLiJFKQoRU1KtjOGISqVEQgynhMc8YTJHXFLNpZCK5JKblUGEiTFCRBmuJOESa0PoCNz3vlvXfLfah6yyfh9d1rppfRYjISijqAPv_oGbpnV1ly0jMYspYmLv9tBDyjXeO22yrbOVdLsMo2zfdHZsumNvD4ZtXunVH3motgNueuBLurV2R6B__wXGX4Bj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274730462</pqid></control><display><type>article</type><title>The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Agents</title><source>Karger Journals</source><source>MEDLINE</source><creator>Lin, Congrong ; Ke, Xiaogang ; Cvetanovic, Ivana ; Ranade, Vasant ; Somberg, John</creator><creatorcontrib>Lin, Congrong ; Ke, Xiaogang ; Cvetanovic, Ivana ; Ranade, Vasant ; Somberg, John</creatorcontrib><description>Background: Hyperkalemia is a potentially life-threatening disorder frequently occurring in hospitalized patients. The ischemic myocardium releases potassium into the extracellular space which can cause regional hyperkalemia. These changes may modify the effects of anti-arrhythmic drugs acting on the rapid component of the delayed rectifier potassium current (IKr). We evaluated the influence of increased extracellular potassium concentration [K + ] e on IKr inhibition by amiodarone, azimilide, dofetilide, quinidine and sotalol. Methods and Results: Experiments were performed at room temperature. IKr current was studied by using HERG gene expressed in Xenopus oocytes as a model of cardiac IKr. Two-electrode voltage clamp technique was employed. The recording bath solutions contained either 5 or 10 mmol/l KCl. Amiodarone, azimilide, dofetilide, quinidine and sotalol all produced a dose-dependent inhibition of HERG current. At 5 mmol/l [K + ] e , the IC 50 was 37.0 ± 12.5 µM for amiodarone, 5.8 ± 0.4 µM for azimilide, 1.5 ± 0. 2 µM for dofetilide, 9.1 ± 1.5 µM for quinidine, and 5.1 ± 0.8 mM for sotalol. Raising the extracellular potassium to 10 mmol/l, HERG block by azimilide, dofetilide, quinidine and sotalol was significantly decreased, while the block by amiodarone was unchanged. The differences in the percentage current block produced by 3 µM drugs at 5 and 10 mmol/l [K + ] e were: –0.9% for amiodarone, 13.8% for quinidine, 20.5% for azimilide, and 16.2% for dofetilide. The differences in percentage block between 5 and 10 mmol/l [K + ] e by sotalol 10 and 30 mM were 7.1 and 5.6%. At 10 mmol/l [K + ] e , the IC 50 was increased for azimilide, dofetilide, quinidine and sotalol but not for amiodarone; the IC 50 was 24.7 ± 7.4 µM for amiodarone, 29.3 ± 3.9 µM for azimilide, 2.7 ± 0.2 µM for dofetilide, 27.6 ± 4.0 µM for quinidine, and 7.2 ± 1.7 mM for sotalol. Conclusion: Inhibition of IKr by azimilide, quinidine, dofetilide and sotalol was diminished by increasing [K + ] e , while the inhibition by amiodarone was unchanged at normal and high [K + ] e . The differential effects of azimilide, dofetilide, quinidine and sotalol at normal and high [K + ] e could be pro-arrhythmic by favoring re-entry arrhythmias. These results further support the unique electrophysiological effect of amiodarone.</description><identifier>ISSN: 0008-6312</identifier><identifier>EISSN: 1421-9751</identifier><identifier>DOI: 10.1159/000095596</identifier><identifier>PMID: 16960444</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Action Potentials - drug effects ; Animals ; Anti-Arrhythmia Agents - pharmacology ; Cardiac arrhythmia ; Cells, Cultured ; Disease Models, Animal ; Electrophysiology ; Extracellular Matrix - drug effects ; Extracellular Matrix - metabolism ; Female ; Hydantoins ; Hyperkalemia - drug therapy ; Hyperkalemia - physiopathology ; Imidazolidines - pharmacology ; Inhibitor drugs ; Oocytes - cytology ; Oocytes - drug effects ; Original Research ; Pharmacology ; Phenethylamines - pharmacology ; Piperazines - pharmacology ; Potassium ; Potassium Channels - drug effects ; Potassium Channels, Voltage-Gated - drug effects ; Probability ; Sensitivity and Specificity ; Sotalol - pharmacology ; Sulfonamides - pharmacology ; Xenopus laevis</subject><ispartof>Cardiology, 2007-01, Vol.108 (1), p.18-27</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>Copyright 2007 S. Karger AG, Basel.</rights><rights>Copyright (c) 2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-4cacdff503acc692f53257594ab05a3e5a6ac2ba5fdf02468002cf5ca25a1ef23</citedby><cites>FETCH-LOGICAL-c330t-4cacdff503acc692f53257594ab05a3e5a6ac2ba5fdf02468002cf5ca25a1ef23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16960444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Congrong</creatorcontrib><creatorcontrib>Ke, Xiaogang</creatorcontrib><creatorcontrib>Cvetanovic, Ivana</creatorcontrib><creatorcontrib>Ranade, Vasant</creatorcontrib><creatorcontrib>Somberg, John</creatorcontrib><title>The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Agents</title><title>Cardiology</title><addtitle>Cardiology</addtitle><description>Background: Hyperkalemia is a potentially life-threatening disorder frequently occurring in hospitalized patients. The ischemic myocardium releases potassium into the extracellular space which can cause regional hyperkalemia. These changes may modify the effects of anti-arrhythmic drugs acting on the rapid component of the delayed rectifier potassium current (IKr). We evaluated the influence of increased extracellular potassium concentration [K + ] e on IKr inhibition by amiodarone, azimilide, dofetilide, quinidine and sotalol. Methods and Results: Experiments were performed at room temperature. IKr current was studied by using HERG gene expressed in Xenopus oocytes as a model of cardiac IKr. Two-electrode voltage clamp technique was employed. The recording bath solutions contained either 5 or 10 mmol/l KCl. Amiodarone, azimilide, dofetilide, quinidine and sotalol all produced a dose-dependent inhibition of HERG current. At 5 mmol/l [K + ] e , the IC 50 was 37.0 ± 12.5 µM for amiodarone, 5.8 ± 0.4 µM for azimilide, 1.5 ± 0. 2 µM for dofetilide, 9.1 ± 1.5 µM for quinidine, and 5.1 ± 0.8 mM for sotalol. Raising the extracellular potassium to 10 mmol/l, HERG block by azimilide, dofetilide, quinidine and sotalol was significantly decreased, while the block by amiodarone was unchanged. The differences in the percentage current block produced by 3 µM drugs at 5 and 10 mmol/l [K + ] e were: –0.9% for amiodarone, 13.8% for quinidine, 20.5% for azimilide, and 16.2% for dofetilide. The differences in percentage block between 5 and 10 mmol/l [K + ] e by sotalol 10 and 30 mM were 7.1 and 5.6%. At 10 mmol/l [K + ] e , the IC 50 was increased for azimilide, dofetilide, quinidine and sotalol but not for amiodarone; the IC 50 was 24.7 ± 7.4 µM for amiodarone, 29.3 ± 3.9 µM for azimilide, 2.7 ± 0.2 µM for dofetilide, 27.6 ± 4.0 µM for quinidine, and 7.2 ± 1.7 mM for sotalol. Conclusion: Inhibition of IKr by azimilide, quinidine, dofetilide and sotalol was diminished by increasing [K + ] e , while the inhibition by amiodarone was unchanged at normal and high [K + ] e . The differential effects of azimilide, dofetilide, quinidine and sotalol at normal and high [K + ] e could be pro-arrhythmic by favoring re-entry arrhythmias. These results further support the unique electrophysiological effect of amiodarone.</description><subject>Action Potentials - drug effects</subject><subject>Animals</subject><subject>Anti-Arrhythmia Agents - pharmacology</subject><subject>Cardiac arrhythmia</subject><subject>Cells, Cultured</subject><subject>Disease Models, Animal</subject><subject>Electrophysiology</subject><subject>Extracellular Matrix - drug effects</subject><subject>Extracellular Matrix - metabolism</subject><subject>Female</subject><subject>Hydantoins</subject><subject>Hyperkalemia - drug therapy</subject><subject>Hyperkalemia - physiopathology</subject><subject>Imidazolidines - pharmacology</subject><subject>Inhibitor drugs</subject><subject>Oocytes - cytology</subject><subject>Oocytes - drug effects</subject><subject>Original Research</subject><subject>Pharmacology</subject><subject>Phenethylamines - pharmacology</subject><subject>Piperazines - pharmacology</subject><subject>Potassium</subject><subject>Potassium Channels - drug effects</subject><subject>Potassium Channels, Voltage-Gated - drug effects</subject><subject>Probability</subject><subject>Sensitivity and Specificity</subject><subject>Sotalol - pharmacology</subject><subject>Sulfonamides - pharmacology</subject><subject>Xenopus laevis</subject><issn>0008-6312</issn><issn>1421-9751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkEtLAzEUhYMotlYXrgUJLgQXo3lPZzmUaosFXVS3QyZNOqnzqEkG7L93ypQK3s3lXL57OBwArjF6xJgnT6ibhPNEnIAhZgRHSczxKRh253EkKCYDcOH9ppMsZuQcDLBIBGKMDcHnstBwaoxWATYGzuy6gNOf4KTSZdmW0sH3JkjvbVvBpobzVwfndWFzG2wn8x1M62Cj1LliF4rKKpiudR38JTgzsvT66rBH4ON5upzMosXby3ySLiJFKQoRU1KtjOGISqVEQgynhMc8YTJHXFLNpZCK5JKblUGEiTFCRBmuJOESa0PoCNz3vlvXfLfah6yyfh9d1rppfRYjISijqAPv_oGbpnV1ly0jMYspYmLv9tBDyjXeO22yrbOVdLsMo2zfdHZsumNvD4ZtXunVH3motgNueuBLurV2R6B__wXGX4Bj</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Lin, Congrong</creator><creator>Ke, Xiaogang</creator><creator>Cvetanovic, Ivana</creator><creator>Ranade, Vasant</creator><creator>Somberg, John</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Agents</title><author>Lin, Congrong ; Ke, Xiaogang ; Cvetanovic, Ivana ; Ranade, Vasant ; Somberg, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-4cacdff503acc692f53257594ab05a3e5a6ac2ba5fdf02468002cf5ca25a1ef23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Action Potentials - drug effects</topic><topic>Animals</topic><topic>Anti-Arrhythmia Agents - pharmacology</topic><topic>Cardiac arrhythmia</topic><topic>Cells, Cultured</topic><topic>Disease Models, Animal</topic><topic>Electrophysiology</topic><topic>Extracellular Matrix - drug effects</topic><topic>Extracellular Matrix - metabolism</topic><topic>Female</topic><topic>Hydantoins</topic><topic>Hyperkalemia - drug therapy</topic><topic>Hyperkalemia - physiopathology</topic><topic>Imidazolidines - pharmacology</topic><topic>Inhibitor drugs</topic><topic>Oocytes - cytology</topic><topic>Oocytes - drug effects</topic><topic>Original Research</topic><topic>Pharmacology</topic><topic>Phenethylamines - pharmacology</topic><topic>Piperazines - pharmacology</topic><topic>Potassium</topic><topic>Potassium Channels - drug effects</topic><topic>Potassium Channels, Voltage-Gated - drug effects</topic><topic>Probability</topic><topic>Sensitivity and Specificity</topic><topic>Sotalol - pharmacology</topic><topic>Sulfonamides - pharmacology</topic><topic>Xenopus laevis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Congrong</creatorcontrib><creatorcontrib>Ke, Xiaogang</creatorcontrib><creatorcontrib>Cvetanovic, Ivana</creatorcontrib><creatorcontrib>Ranade, Vasant</creatorcontrib><creatorcontrib>Somberg, John</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Congrong</au><au>Ke, Xiaogang</au><au>Cvetanovic, Ivana</au><au>Ranade, Vasant</au><au>Somberg, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Agents</atitle><jtitle>Cardiology</jtitle><addtitle>Cardiology</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>108</volume><issue>1</issue><spage>18</spage><epage>27</epage><pages>18-27</pages><issn>0008-6312</issn><eissn>1421-9751</eissn><abstract>Background: Hyperkalemia is a potentially life-threatening disorder frequently occurring in hospitalized patients. The ischemic myocardium releases potassium into the extracellular space which can cause regional hyperkalemia. These changes may modify the effects of anti-arrhythmic drugs acting on the rapid component of the delayed rectifier potassium current (IKr). We evaluated the influence of increased extracellular potassium concentration [K + ] e on IKr inhibition by amiodarone, azimilide, dofetilide, quinidine and sotalol. Methods and Results: Experiments were performed at room temperature. IKr current was studied by using HERG gene expressed in Xenopus oocytes as a model of cardiac IKr. Two-electrode voltage clamp technique was employed. The recording bath solutions contained either 5 or 10 mmol/l KCl. Amiodarone, azimilide, dofetilide, quinidine and sotalol all produced a dose-dependent inhibition of HERG current. At 5 mmol/l [K + ] e , the IC 50 was 37.0 ± 12.5 µM for amiodarone, 5.8 ± 0.4 µM for azimilide, 1.5 ± 0. 2 µM for dofetilide, 9.1 ± 1.5 µM for quinidine, and 5.1 ± 0.8 mM for sotalol. Raising the extracellular potassium to 10 mmol/l, HERG block by azimilide, dofetilide, quinidine and sotalol was significantly decreased, while the block by amiodarone was unchanged. The differences in the percentage current block produced by 3 µM drugs at 5 and 10 mmol/l [K + ] e were: –0.9% for amiodarone, 13.8% for quinidine, 20.5% for azimilide, and 16.2% for dofetilide. The differences in percentage block between 5 and 10 mmol/l [K + ] e by sotalol 10 and 30 mM were 7.1 and 5.6%. At 10 mmol/l [K + ] e , the IC 50 was increased for azimilide, dofetilide, quinidine and sotalol but not for amiodarone; the IC 50 was 24.7 ± 7.4 µM for amiodarone, 29.3 ± 3.9 µM for azimilide, 2.7 ± 0.2 µM for dofetilide, 27.6 ± 4.0 µM for quinidine, and 7.2 ± 1.7 mM for sotalol. Conclusion: Inhibition of IKr by azimilide, quinidine, dofetilide and sotalol was diminished by increasing [K + ] e , while the inhibition by amiodarone was unchanged at normal and high [K + ] e . The differential effects of azimilide, dofetilide, quinidine and sotalol at normal and high [K + ] e could be pro-arrhythmic by favoring re-entry arrhythmias. These results further support the unique electrophysiological effect of amiodarone.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>16960444</pmid><doi>10.1159/000095596</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-6312
ispartof Cardiology, 2007-01, Vol.108 (1), p.18-27
issn 0008-6312
1421-9751
language eng
recordid cdi_karger_primary_95596
source Karger Journals; MEDLINE
subjects Action Potentials - drug effects
Animals
Anti-Arrhythmia Agents - pharmacology
Cardiac arrhythmia
Cells, Cultured
Disease Models, Animal
Electrophysiology
Extracellular Matrix - drug effects
Extracellular Matrix - metabolism
Female
Hydantoins
Hyperkalemia - drug therapy
Hyperkalemia - physiopathology
Imidazolidines - pharmacology
Inhibitor drugs
Oocytes - cytology
Oocytes - drug effects
Original Research
Pharmacology
Phenethylamines - pharmacology
Piperazines - pharmacology
Potassium
Potassium Channels - drug effects
Potassium Channels, Voltage-Gated - drug effects
Probability
Sensitivity and Specificity
Sotalol - pharmacology
Sulfonamides - pharmacology
Xenopus laevis
title The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Agents
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T05%3A17%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20High%20Extracellular%20Potassium%20on%20IKr%20Inhibition%20by%20Anti-Arrhythmic%20Agents&rft.jtitle=Cardiology&rft.au=Lin,%20Congrong&rft.date=2007-01-01&rft.volume=108&rft.issue=1&rft.spage=18&rft.epage=27&rft.pages=18-27&rft.issn=0008-6312&rft.eissn=1421-9751&rft_id=info:doi/10.1159/000095596&rft_dat=%3Cproquest_karge%3E1313138901%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274730462&rft_id=info:pmid/16960444&rfr_iscdi=true